Sanofi Management

Management Kriterienprüfungen 3/4

Sanofi's CEO ist Paul Hudson , ernannt in Sep 2019, hat eine Amtszeit von 4.75 Jahren. Die jährliche Gesamtvergütung beträgt €10.57M , bestehend aus 13.2% Gehalt und 86.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.006% der Aktien des Unternehmens, im Wert von €6.26M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.3 Jahre bzw. 4.2 Jahre.

Wichtige Informationen

Paul Hudson

Geschäftsführender

€10.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	13.2%
Amtszeit als Geschäftsführer	4.8yrs
Eigentum des Geschäftsführers	0.006%
Durchschnittliche Amtszeit des Managements	4.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.3yrs

Jüngste Management Updates

Recent updates

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Apr 13

Sanofi's (EPA:SAN) Price Is Right But Growth Is Lacking

Jan 06

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Paul Hudson im Vergleich zu den Einnahmen von Sanofi verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	€5b
Dec 31 2023	€11m	€1m	€5b
Sep 30 2023	n/a	n/a	€9b
Jun 30 2023	n/a	n/a	€9b
Mar 31 2023	n/a	n/a	€8b
Dec 31 2022	€11m	€1m	€8b
Sep 30 2022	n/a	n/a	€6b
Jun 30 2022	n/a	n/a	€7b
Mar 31 2022	n/a	n/a	€7b
Dec 31 2021	€11m	€1m	€6b
Sep 30 2021	n/a	n/a	€6b
Jun 30 2021	n/a	n/a	€6b
Mar 31 2021	n/a	n/a	€12b
Dec 31 2020	€11m	€1m	€12b
Sep 30 2020	n/a	n/a	€11b
Jun 30 2020	n/a	n/a	€11b
Mar 31 2020	n/a	n/a	€3b
Dec 31 2019	€6m	€433k	€3b

Vergütung im Vergleich zum Markt: PaulDie Gesamtvergütung ($USD11.36M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt French ($USD4.76M).

Entschädigung vs. Einkommen: PaulDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Paul Hudson (57 yo)

4.8yrs

Amtszeit

€10,571,822

Vergütung

Mr. Paul Hudson serves as Chief Executive Officer of Sanofi at Hoechst Pakistan Limited (formerly known as sanofi-aventis Pakistan Limited). He has been Chief Executive Officer at Sanofi since September 1,...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Paul Hudson	CEO & Director	4.8yrs	€10.57m	0.0057% € 6.4m
François-Xavier Roger	Executive VP & CFO	less than a year	keine Daten	keine Daten
Madeleine Roach	Executive VP & Head of Business Operations	less than a year	keine Daten	keine Daten
Laurent Gilhodes	Principal Accounting Officer and Vice President of Corporate Accounting	no data	keine Daten	keine Daten
Josephine Fubara	Chief Science Officer of Consumer Health Care	no data	keine Daten	keine Daten
Eva Schaefer-Jansen	Head of Investor Relations	no data	keine Daten	keine Daten
Dante Beccaria	Global Compliance Officer & VP	12.3yrs	keine Daten	keine Daten
Roy Papatheodorou	Executive VP & General Counsel	2.4yrs	keine Daten	keine Daten
Josep Catlla	Head of Communications	no data	keine Daten	keine Daten
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	19.9yrs	keine Daten	keine Daten
Natalie Bickford	Executive VP & Chief People Officer	3.9yrs	keine Daten	keine Daten
Marie-Hélène Laimay	Senior Vice President of Audit & Internal Control Assessment	22.2yrs	keine Daten	keine Daten

4.4yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: SANDas Führungsteam des Unternehmens gilt als erfahren (4.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Paul Hudson	CEO & Director	4.8yrs	€10.57m	0.0057% € 6.4m
Jean-François Dehecq	Honorary Chairman	14.2yrs	€4.71m	keine Daten
Serge Weinberg	Honorary Chairman	1.2yrs	€324.96k	0.00013% € 147.9k
Patrick Kron	Independent Director	10.2yrs	€175.75k	0.000080% € 91.0k
Lise Kingo	Independent Director	4.3yrs	€148.25k	0.000080% € 91.0k
Frederic Oudea	Independent Chairman	1.2yrs	€573.52k	0.000080% € 91.0k
Fabienne Lecorvaisier	Independent Director	11.2yrs	€156.50k	0.000080% € 91.0k
Gilles Schnepp	Independent Director	2.6yrs	€175.75k	0.000080% € 91.0k
Rachel Duan	Independent Director	4.3yrs	€145.50k	0.000080% € 91.0k
Barbara Lavernos	Director	3.3yrs	€134.50k	0.000080% € 91.0k
Christophe Babule	Director	5.4yrs	€134.50k	0.000080% € 91.0k
Wolfgang Laux	Employee Representative Director	3.3yrs	€107.00k	0.00031% € 352.7k

4.3yrs

Durchschnittliche Betriebszugehörigkeit

61.5yo

Durchschnittliches Alter

Erfahrener Vorstand: SANDie Vorstandsmitglieder gelten als erfahren (4.2 Jahre durchschnittliche Amtszeit).

Sanofi Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

Sanofi Announces CFO Changes, Effective April 1, 2024

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Upcoming dividend of €3.76 per share

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 17%

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Full year 2023 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Consensus EPS estimates increase by 13%

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

New minor risk - Profit margin trend

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi's (EPA:SAN) Price Is Right But Growth Is Lacking

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter